Breaking News, Collaborations & Alliances

Lipocine Enters Exclusive Supply and Distribution Agreement with Pharmalink

Will commercialize TLANDO in the Gulf Cooperation Council (GCC) countries.

Lipocine Inc., a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, has announced an exclusive supply and distribution agreement with Pharmalink to commercialize TLANDO, its oral testosterone replacement therapy, in the Gulf Cooperation Council (GCC) countries Saudi Arabia, Kuwait, the United Arab Emirates (UAE), Qatar, Bahrain, and Oman.
 
Under the terms of the agreement, Lipocine received an upfront payment from Pharmalink and, upon Marketing Authorizations (MA) in individual GCC countries, Lipocine will provide TLANDO drug product to Pharmalink at an agreed transfer price. Pharmalink will have the exclusive rights to TLANDO throughout the GCC region and will be responsible for promotion, distribution and sale of the product in the territory.
 
“We are very pleased to partner with Pharmalink to bring TLANDO to the GCC region,” said Dr. Mahesh Patel, President and CEO of Lipocine Inc. “This agreement is aligned with our global strategy to expand the availability of TLANDO and make it broadly accessible.  Pharmalink’s expertise and established network in GCC make them an ideal partner to support the adoption and growth of TLANDO in the region.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters